


## NH2-PEG5-OH

Cat. No.:	HY-129637
CAS No.:	34188-11-9
Molecular Formula:	C <sub>10</sub> H <sub>23</sub> NO <sub>5</sub>
Molecular Weight:	237.29
Target:	PROTAC Linkers; ADC Linker
Pathway:	PROTAC; Antibody-drug Conjugate/ADC Related
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (421.43 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	4.2143 mL	21.0713 mL	42.1425 mL	
		5 mM	0.8429 mL	4.2143 mL	8.4285 mL	
		10 mM	0.4214 mL	2.1071 mL	4.2143 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

Description	NH2-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . NH2-PEG5-OH is also a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[2]</sup> .	
IC <sub>50</sub> & Target	PEGs	Non-cleavable
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

---

## REFERENCES

[1]. Nathanael Gray, et al. Bifunctional molecules for degradation of egfr and methods of use. WO2017185036A1.

[2]. Nianhe Han, et al. Derivatives of dolastatin 10 and uses thereof. WO2016192527A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA